Nevertheless, resistance to AR-targeting therapies remains a significant challenge in PCa management, often driven by reactivation of the AR axis via amplification, mutations, or the expression of AR variants (ARVs) that maintain constitutive activity independent of androgens, as observed in castration-resistant prostate cancer (Messner et al., 2020). This evidence concerns the gene AR and Familial prostate cancer.